FCPM III SERVICES B.V.
13F Reported Value
ⓘ$750.4M
Holdings
11
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
FCPM III SERVICES B.V. disclosed 11 positions worth $750.4M in its Form 13F-HR for Q2 2026, led by $NAMS (NewAmsterdam Pharma Co N.V.) at 38.3% of the equity portfolio, followed by $MPLT and $DYN. During the quarter the fund opened 1 new position and exited 0 — including a new stake in $AURA. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from FCPM III SERVICES B.V.’s Form 13F-HR filing with the SEC under CIK 2013410.
AI Fund Analysis
StableSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- —
Quality
$287.7M8,490,353 sh - —
Quality
$115.6M3,226,400 sh - —
Quality
$85.5M3,848,256 sh - —
Quality
$75.8M4,117,354 sh - —
Quality
$63.5M2,441,000 sh - —
Quality
$31.1M2,808,368 sh - 9.6
Quality
$30.2M1,677,852 sh - —
Quality
$28.8M4,053,775 sh - —
Quality
$16.7M9,632,561 sh - —
Quality
$14.7M3,468,430 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 NewAmsterdam Pharma Co N.V.$NAMS | — | $287.7M | 8,490,353 |
 MapLight Therapeutics, Inc.$MPLT | — | $115.6M | 3,226,400 |
 Dyne Therapeutics, Inc.$DYN | — | $85.5M | 3,848,256 |
 Vor Biopharma Inc.$VOR | — | $75.8M | 4,117,354 |
 Damora Therapeutics, Inc.$DMRA | — | $63.5M | 2,441,000 |
 Replimune Group, Inc.$REPL | — | $31.1M | 2,808,368 |
 CRESCENT BIOPHARMA, INC.$CBIO | 9.6 | $30.2M | 1,677,852 |
 Aura Biosciences, Inc.$AURA | — | $28.8M | 4,053,775 |
 enGene Therapeutics Inc.$ENGN | — | $16.7M | 9,632,561 |
 BICYCLE THERAPEUTICS PLC$BCYC | — | $14.7M | 3,468,430 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of FCPM III SERVICES B.V.'s 11 positions.
Showing top 10 of 11 holdings.
Sector Allocation
Healthcare
$750.4M
Full Holdings — FCPM III SERVICES B.V. (Q2 2026)
All 11 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $NAMS | NewAmsterdam Pharma Co N.V. | $287.7M | 38.3% | -8% | — |
| 2 | $MPLT | MapLight Therapeutics, Inc. | $115.6M | 15.4% | +0% | — |
| 3 | $DYN | Dyne Therapeutics, Inc. | $85.5M | 11.4% | -17% | — |
| 4 | $VOR | Vor Biopharma Inc. | $75.8M | 10.1% | +0% | — |
| 5 | $DMRA | Damora Therapeutics, Inc. | $63.5M | 8.5% | +0% | — |
| 6 | $REPL | Replimune Group, Inc. | $31.1M | 4.1% | +0% | — |
| 7 | $CBIO | CRESCENT BIOPHARMA, INC. | $30.2M | 4.0% | +0% | 9.6 |
| 8 | $AURA | Aura Biosciences, Inc. | $28.8M | 3.8% | NEW | — |
| 9 | $ENGN | enGene Therapeutics Inc. | $16.7M | 2.2% | +0% | — |
| 10 | $BCYC | BICYCLE THERAPEUTICS PLC | $14.7M | 2.0% | +0% | — |
| 11 | $ENGN | enGene Therapeutics Inc. | $834,376 | 0.1% | +0% | — |
New Positions (1)
$AURA Aura Biosciences, Inc.$28.8MBrowse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for FCPM III SERVICES B.V. including:
Track FCPM III SERVICES B.V.'s Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for FCPM III SERVICES B.V. and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: FCPM III SERVICES B.V.
13F Pro is an AI hedge fund tracker and stock research platform. For FCPM III SERVICES B.V. (SEC CIK: 2013410), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in FCPM III SERVICES B.V.'s portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.